Sucampo Pharmaceuticals, Inc.
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
27.3%
3 terminated/withdrawn out of 11 trials
72.7%
-13.8% vs industry average
73%
8 trials in Phase 3/4
113%
9 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
Role: collaborator
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Role: collaborator
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
Role: collaborator
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
Role: collaborator
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
Role: collaborator
Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation
Role: collaborator
Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
Role: collaborator
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
Role: collaborator
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
Role: collaborator
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
Role: collaborator
Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
Role: collaborator
All 11 trials loaded